Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM12470 in Type 1 and Type 2 Diabetes Mellitus
NCT03332849Phase 1Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of HM12470 in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Hanmi Pharmaceutical. Primary endpoint: Number of participants with adverse events at 1 month. Status: unknown.
02
Drugs
HM12470
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03332849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332849.